120 related articles for article (PubMed ID: 16124950)
1. A contemporary assessment of low-molecular-weight heparin for the treatment of acute coronary syndromes: factoring in new trials and meta-analysis data.
Topol EJ
Am Heart J; 2005 Apr; 149(4 Suppl):S100-6. PubMed ID: 16124950
[No Abstract] [Full Text] [Related]
2. A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes.
Califf RM; Petersen JL; Hasselblad V; Mahaffey KW; Ferguson JJ
Am Heart J; 2005 Apr; 149(4 Suppl):S91-9. PubMed ID: 16124953
[TBL] [Abstract][Full Text] [Related]
3. Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Mahaffey KW; Ferguson JJ
Am Heart J; 2005 Apr; 149(4 Suppl):S81-90. PubMed ID: 16124952
[TBL] [Abstract][Full Text] [Related]
4. Contemporary view of the acute coronary syndromes.
Moustapha A; Anderson HV
J Invasive Cardiol; 2003 Feb; 15(2):71-9. PubMed ID: 12556619
[No Abstract] [Full Text] [Related]
5. Low-molecular weight heparins - the mainstay of anti-coagulant therapy.
Cardiovasc J S Afr; 2002; 13(2):80-2. PubMed ID: 12166360
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
White HD; Kleiman NS; Mahaffey KW; Lokhnygina Y; Pieper KS; Chiswell K; Cohen M; Harrington RA; Chew DP; Petersen JL; Berdan LG; Aylward PE; Nessel CC; Ferguson JJ; Califf RM
Am Heart J; 2006 Dec; 152(6):1042-50. PubMed ID: 17161049
[TBL] [Abstract][Full Text] [Related]
7. Improving outcome in acute coronary syndromes - as good as it gets?
Purcell H; Fox KM
Eur Heart J; 1999 Nov; 20(21):1533-7. PubMed ID: 10529321
[No Abstract] [Full Text] [Related]
8. The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial.
Becker RC
Am Heart J; 2005 Aug; 150(2):189-92. PubMed ID: 16086916
[No Abstract] [Full Text] [Related]
9. Enoxaparin in acute coronary syndromes.
Lee S; Gibson CM
Expert Rev Cardiovasc Ther; 2007 May; 5(3):387-99. PubMed ID: 17489664
[TBL] [Abstract][Full Text] [Related]
10. Acute coronary syndromes.
Cequier A; Gómez-Hospital JA; Gonzalez-Costello J
N Engl J Med; 2009 Aug; 361(9):926; author reply 927. PubMed ID: 19714783
[No Abstract] [Full Text] [Related]
11. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
Kandzari DE
Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
[TBL] [Abstract][Full Text] [Related]
12. Fondaparinux in the treatment of acute coronary syndromes: evidence from OASIS 5 and 6.
Karthikeyan G; Mehta SR; Eikelboom JW
Expert Rev Cardiovasc Ther; 2009 Mar; 7(3):241-9. PubMed ID: 19296760
[TBL] [Abstract][Full Text] [Related]
13. Anti-Xa activity with low-molecular-weight heparin, enoxaparin, during pregnancy in women with mechanical heart valves.
Izaguirre R; De La Peña A; Ramírez A; Cortina E; Huerta M; Salazar E
Proc West Pharmacol Soc; 2002; 45():127-8. PubMed ID: 12434554
[No Abstract] [Full Text] [Related]
14. Pursuing progress in acute coronary syndromes.
Armstrong PW
Circulation; 1999 Oct; 100(15):1586-9. PubMed ID: 10517727
[No Abstract] [Full Text] [Related]
15. Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
Chew DP; Huang Z; Pieper KS; White H; Mahaffey KW; Ferguson JJ; Califf RM; Aylward PG
Am Heart J; 2008 Feb; 155(2):239-44. PubMed ID: 18215592
[TBL] [Abstract][Full Text] [Related]
16. The role of low-molecular-weight heparins in the management of unstable angina and non-ST-segment elevation myocardial infarction.
Cohen M
J Thromb Thrombolysis; 2001 Apr; 11(2):171-4. PubMed ID: 11406733
[No Abstract] [Full Text] [Related]
17. Use of heparins in Non-ST-elevation acute coronary syndromes.
Gore JM; Spencer FA; Goldberg RJ; Kennelly BM; Fox KA; Allegrone J; Eagle KA; Anderson FA; Steg PG;
Am J Med; 2007 Jan; 120(1):63-71. PubMed ID: 17208081
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
[TBL] [Abstract][Full Text] [Related]
19. Deep venous thrombosis: outpatient therapy with low-molecular-weight heparin.
Tapson VF
Manag Care; 1999 Dec; 8 Suppl():2-6. PubMed ID: 11729399
[No Abstract] [Full Text] [Related]
20. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
